AMPH vs HSTM: fair value comparison
Amphastar Pharmaceuticals, Inc. and HealthStream, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, AMPH currently sits closer to the top of our ranking by discount to fair value.
| AMPH | HSTM | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $25.87 | $33.13 |
| 12-month range | $16.87–$29.40 | $19.88–$33.75 |
| Rank by discount to fair value | #27 of 108 Healthcare | #31 of 108 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | B |
| Leverage | Moderate | Low |
| Margin trend | Contracting | Stable |
| Revenue growth | Modest | Modest |
| RSI zone | Neutral | Overbought |
| 50/200-day trend | Uptrend | Uptrend |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The top quarter |
Full single-stock breakdowns: AMPH fair value analysis · HSTM fair value analysis